CANbridge to Continue CAN008 Phase II Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee

CANbridge Pharmaceuticals, Inc. announced that, based on the interim analysis recommendation of the independent data monitoring committee, it plans to continue the ongoing Phase II study of CAN008 in patients with newly diagnosed glioblastoma multiforme in China to completion.